Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies

With more than 20 anti-PD-1/PD-L1 antibodies currently marketed, anti-PD-1 therapy has become a cornerstone of tumor immunotherapy. These agents, however, exhibit notable disparities in their characteristics and clinical performance. For instance, in the field of small cell lung cancer (SCLC) where...

Full description

Saved in:
Bibliographic Details
Main Authors: Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:mAbs
Subjects:
Anti-PD-1/PD-L1
serplulimab
tumor immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2024.2419838
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items